Vitamin D supplementation was associated with an 85% lower risk of liver and bile duct cancer in a study of 160 patients with primary sclerosing cholangitis, according to Gram Research analysis. Over five years, only 1.1% of patients taking vitamin D developed cancer compared to 11.5% of those not taking supplements, suggesting vitamin D may offer significant protection for this high-risk group.
A Gram Research analysis of 160 patients with primary sclerosing cholangitis (a rare liver disease) found that taking vitamin D supplements was linked to an 85% lower risk of developing liver and bile duct cancer over seven years. Among patients taking vitamin D, only 1.1% developed cancer within five years, compared to 11.5% of those who didn’t take supplements. While this is promising news for a high-risk group, researchers emphasize these findings need confirmation through larger studies before making universal recommendations.
Key Statistics
A 2026 cohort study of 160 patients with primary sclerosing cholangitis found that vitamin D supplementation was associated with an 85% lower risk of developing liver and bile duct cancer (hazard ratio 0.15, 95% CI 0.03-0.41).
Among 160 PSC patients followed for a median of 7 years, the 5-year cumulative incidence of liver and bile duct cancer was 1.1% in those receiving vitamin D supplementation versus 11.5% in those without supplementation (p<0.01).
In a 2026 analysis of 160 patients with primary sclerosing cholangitis, vitamin D’s protective effect against hepatobiliary malignancy remained consistent across baseline vitamin D levels, with hazard ratios of 0.12 for those with deficiency and 0.18 for those with adequate levels.
The Quick Take
- What they studied: Whether taking vitamin D supplements helps prevent liver and bile duct cancer in people with primary sclerosing cholangitis, a condition where the bile ducts in the liver become scarred and damaged.
- Who participated: 160 patients (average age 42, mostly men) with primary sclerosing cholangitis who were followed for an average of 7 years. About half were taking vitamin D supplements at the start of the study.
- Key finding: Patients taking vitamin D supplements had an 85% lower risk of developing liver or bile duct cancer compared to those not taking supplements. Only 1.1% of vitamin D users developed cancer within 5 years versus 11.5% of non-users.
- What it means for you: If you have primary sclerosing cholangitis, vitamin D supplementation may significantly reduce your cancer risk, but talk to your doctor before starting supplements. This finding is encouraging but needs larger studies to confirm it works for everyone.
The Research Details
Researchers looked back at medical records from 160 patients with primary sclerosing cholangitis who were treated at a major liver transplant center between 2010 and 2020. They tracked which patients took vitamin D supplements and which didn’t, then followed everyone for about 7 years to see who developed liver or bile duct cancer.
To make fair comparisons, the researchers used a statistical technique called inverse probability weighting to account for differences between the two groups (like age, disease severity, and other health factors). They also used special statistical models that treated death and liver transplants as competing events—meaning they acknowledged that some patients might die or need transplants before developing cancer, which would prevent cancer from developing.
This approach allowed researchers to estimate how much vitamin D supplementation actually reduced cancer risk, separate from other factors that might affect outcomes.
This study design is important because primary sclerosing cholangitis patients have a very high risk of developing liver and bile duct cancer—much higher than the general population. By following real patients over many years and using advanced statistical methods to account for confusing factors, researchers could identify a potential protective effect that might not show up in shorter studies. The competing risks analysis was especially important because many PSC patients die or need transplants, which could mask the true cancer risk.
Strengths: This was a real-world study of actual patients followed over 7 years, which provides strong evidence. The researchers used rigorous statistical methods to account for differences between groups. Limitations: The study was relatively small (160 patients) and conducted at a single medical center, so results might not apply everywhere. It’s observational, meaning we can’t prove vitamin D caused the lower cancer risk—patients taking supplements might have been healthier or more health-conscious in other ways. The study doesn’t explain how vitamin D might prevent cancer, only that it appears associated with lower risk.
What the Results Show
Over the 7-year follow-up period, 15 patients developed liver or bile duct cancer. Patients taking vitamin D supplements had an 85% lower risk of developing this cancer compared to those not taking supplements (the risk was reduced from a hazard ratio of 1.0 to 0.15-0.16, depending on the analysis method used).
When researchers looked at 5-year cancer rates specifically, the difference was striking: only 1.1% of patients taking vitamin D developed cancer within 5 years, compared to 11.5% of those not taking supplements. This means vitamin D users had about a 10-fold lower cancer rate.
Interestingly, the protective effect of vitamin D appeared consistent regardless of patients’ baseline vitamin D blood levels. Even patients who started with low vitamin D levels (<30 ng/mL) showed similar cancer risk reduction when they took supplements, as did those who started with adequate levels (≥30 ng/mL).
The researchers also accounted for the fact that some patients died or received liver transplants during the study, which could have prevented cancer from developing. Even after accounting for these competing events, vitamin D supplementation remained strongly protective against cancer.
The study found that vitamin D’s protective effect was consistent across different patient subgroups, suggesting the benefit wasn’t limited to specific types of patients. The association held true whether patients had low, normal, or higher baseline vitamin D levels, indicating that supplementation may help regardless of starting point. The researchers also noted that 47.5% of patients in the study were already taking vitamin D at baseline, suggesting some awareness of its potential benefits in this patient population.
Previous research has shown that vitamin D deficiency is linked to increased cancer risk in many organ systems, but its specific role in liver and bile duct cancer in PSC patients was unclear. This study is among the first to directly examine vitamin D supplementation in this high-risk group. The findings align with laboratory research showing that vitamin D has anti-inflammatory and anti-cancer properties, though the specific mechanisms in PSC-related cancer remain to be determined. The magnitude of risk reduction (85%) is larger than what’s typically seen in other cancer prevention studies, which suggests either a particularly strong effect in this population or the possibility that other unmeasured factors contributed to the difference.
The study was conducted at a single medical center, so results may not apply to all PSC patients everywhere. With only 160 patients and 15 cancer cases, the study was relatively small, which means the findings could change with a larger group. Because this was an observational study (not a randomized trial where some patients are randomly assigned to take vitamin D), we can’t prove that vitamin D itself caused the lower cancer risk—patients taking supplements might have been different in other unmeasured ways. The study didn’t measure actual vitamin D blood levels in most patients or track how much vitamin D people took, so we don’t know the optimal dose. Finally, the study doesn’t explain the biological mechanism of how vitamin D might prevent cancer in PSC patients.
The Bottom Line
For patients with primary sclerosing cholangitis: Discuss vitamin D supplementation with your hepatologist or gastroenterologist. The evidence suggests potential benefit, but this should be personalized to your situation. For the general population without PSC: This study doesn’t provide evidence to recommend vitamin D specifically for cancer prevention, though adequate vitamin D is important for overall health. Confidence level: Moderate for PSC patients (based on one observational study); Low for general population.
This research is most relevant to patients with primary sclerosing cholangitis, who face significantly elevated cancer risk and might benefit from vitamin D supplementation. Hepatologists and gastroenterologists treating PSC patients should consider these findings when counseling patients. The general public should not interpret this as a reason to take high-dose vitamin D for cancer prevention, as the study was specific to a rare disease. People with other liver diseases should consult their doctors before assuming these findings apply to them.
Cancer prevention is a long-term process. In this study, the protective effect of vitamin D became apparent over years of follow-up. Patients shouldn’t expect immediate benefits but should view vitamin D supplementation as part of long-term disease management. If you start taking vitamin D, maintain consistent use and have regular check-ups with your doctor to monitor your health.
Frequently Asked Questions
Does vitamin D prevent liver cancer in people with primary sclerosing cholangitis?
Research shows vitamin D supplementation was associated with an 85% lower cancer risk in PSC patients, with only 1.1% developing cancer over 5 years versus 11.5% without supplements. However, this was one observational study, so larger trials are needed to confirm causation.
How much vitamin D should I take if I have primary sclerosing cholangitis?
This study doesn’t specify optimal doses. Talk to your hepatologist about appropriate vitamin D supplementation for your situation, as the right amount depends on your baseline levels, other health conditions, and medications. Your doctor may recommend blood tests to guide dosing.
Can vitamin D prevent cancer in people without primary sclerosing cholangitis?
This study only examined PSC patients, a high-risk group. While vitamin D is important for overall health, this research doesn’t provide evidence that supplementation prevents cancer in the general population. Consult your doctor about vitamin D for your specific health situation.
What is primary sclerosing cholangitis and why is cancer risk so high?
PSC is a rare disease where bile ducts in the liver become scarred and damaged, leading to inflammation and liver damage. This chronic inflammation significantly increases the risk of developing liver and bile duct cancer, making preventive strategies like vitamin D supplementation particularly important.
Is this study proof that vitamin D prevents cancer?
No. This observational study shows an association between vitamin D use and lower cancer risk, but doesn’t prove vitamin D caused the reduction. Patients taking supplements might have been healthier in other ways. Larger randomized trials are needed to confirm causation.
Want to Apply This Research?
- Track daily vitamin D supplementation (dose and type) and note any symptoms or health changes. For PSC patients specifically, log any digestive symptoms, fatigue, or concerning signs that should be reported to your doctor.
- If your doctor recommends vitamin D supplementation, set a daily reminder to take your supplement at the same time each day (such as with breakfast). Use the app to log your supplement intake and track consistency over weeks and months.
- Maintain a long-term log of vitamin D supplementation adherence. Schedule regular lab work as recommended by your doctor to monitor vitamin D levels and liver function. Use the app to track appointments and share supplement information with your healthcare team during visits.
This article summarizes research findings and should not replace professional medical advice. Vitamin D supplementation decisions should be made in consultation with your healthcare provider, particularly if you have primary sclerosing cholangitis or other liver conditions. This study was observational and cannot prove that vitamin D prevents cancer. Do not start, stop, or change vitamin D supplementation without discussing it with your doctor. If you have PSC or symptoms of liver disease, seek care from a qualified hepatologist or gastroenterologist.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.